Molecular and cellular biology of small cell lung cancer

Seminars in Oncology

Volumn 30, Issue 1, 2003, Pages 57-71

  Sattler, Martin ^b   Salgia, Ravi ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ALISAMYCIN; CELL SURFACE PROTEIN; CISPLATIN; CYTOTOXIC AGENT; FRAGILE HISTIDINE TRIAD PROTEIN; G PROTEIN COUPLED RECEPTOR; GELDANAMYCIN; GEMCITABINE; IMATINIB; INTEGRIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2A11; NEURAL CELL ADHESION MOLECULE ANTIBODY; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL 2; PROTEIN KINASE C ALPHA; PROTEIN P53; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RAPAMYCIN; RETINOBLASTOMA PROTEIN; RETINOIC ACID RECEPTOR BETA; SEMAXANIB; STEEL FACTOR; SU 6597; TELOMERASE; TEMSIROLIMUS; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; WORTMANNIN;

CELL TRANSFORMATION; CHROMOSOME 3P; CHROMOSOME ABERRATION; CHROMOSOME DELETION; CLINICAL TRIAL; CYTOLOGY; CYTOSKELETON; DRUG RECEPTOR BINDING; DRUG TARGETING; GENE CONTROL; GENE LOCATION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC ANALYSIS; HUMAN; LUNG SMALL CELL CANCER; MOLECULAR BIOLOGY; MOLECULAR MECHANICS; NONHUMAN; ONCOGENE; ONCOGENE MYC; PRIORITY JOURNAL; PROTO ONCOGENE; REVIEW; SIDE EFFECT; SOLID TUMOR; THROMBOEMBOLISM; TUMOR SUPPRESSOR GENE;

EID: 0037330953     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2003.50019     Document Type: Review

References (156)

1. Devereux TR, Taylor JA, Barrett JC: Molecular mechanisms of lung cancer. Chest 109:14S-19S, 1996 (suppl)
2. Hibi K, Takahashi T, Yamakawa K, et al: Three distinct regions involved in 3p deletion in human lung cancer. Oncogene 7:445-449, 1992
3. Otterson G, Lin A, Kaye F: Genetic etiology of lung cancer. Oncology 6:97-112, 1992
4. Kok K, Osinga J, Carritt B, et al: Deletion of a DNA sequence at the chromosomal region 3p21 in all major types of lung cancer. Nature 330:578-581, 1987
5. Naylor SL, Johnson BE, Minna JD, Sakaguchi AY. Loss of heterozygosity of chromosome 3p markers in small-cell lung cancer. Nature 329:451-454, 1987
6. Dammann R, Li C, Yoon JH, et al: Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet 25:315-319, 2000
7. Burbee DG, Forgacs E, Zochbauer-Muller S, et al: Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst 93:691-699, 2001
8. Sozzi G, Veronese M, Negrini M, et al: The FHIT gene at 3p14.2 is abnormal in lung cancer. Cell 85:17-26, 1996
9. Ohta M, Inoue H, Cotticelli MG, et al: The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell 84:587-597, 1996
10. Yunis JJ, Soreng AL: Constitutive fragile sites and cancer. Science 226:1199-1204, 1984
11. Barnes LD, Garrison PN, Siprashvili Z, et al: FHIT, a putative tumor suppressor in humans, is a dinucleoside 5′,5‴-P1,P3-triphosphate hydrolase. Biochemistry 35:11529-11535, 1996
12. Croce CM, Sozzi G, Huebner K: Role of FHIT in human cancer. J Clin Oncol 17:1618-1624, 1999
13. Wistuba, II, Gazdar AF, Minna JD: Molecular genetics of small cell lung carcinoma. Semin Oncol 28:3-13, 2001
14. Mattei MG, Riviere M, Krust A, et al: Chromosomal assignment of retinoic acid receptor (RAR) genes in the human, mouse, and rat genomes. Genomics 10:1061-1069, 1991
15. Virmani AK, Rathi A, Zochbauer-Muller S, et al: Promoter methylation and silencing of the retinoic acid receptor-beta gene in lung carcinomas. J Natl Cancer Inst 92:1303-1307, 2000
16. Harley C, Kim N: Telomerase and cancer, in DeVita VJ, Hellman S, Rosenberg S (eds): Important Advances in Oncology, vol 11. Philadelphia, PA, Lippincott-Raven, 1997, pp 1-11
17. Carbone D: The biology of lung cancer. Semin Oncol 24:388-401, 1997
18. Meyerson M: Role of telomerase in normal and cancer cells. J Clin Oncol 18:2626-2634, 2000
19. Morin GB: The human telomere terminal transferase enzyme is a ribonucleoprotein that synthesizes TTAGGG repeats. Cell 59:521-529, 1989
20. Hiyama K, Ishioka S, Shirotani Y, et al: Alterations in telomeric repeat length in lung cancer are associated with loss of heterozygosity in p53 and rb. Oncogene 10:937-944, 1995
21. Sarvesvaran J, Going JJ, Milroy R, et al: Is small cell lung cancer the perfect target for anti-telomerase treatment? Carcinogenesis 20:1649-1651, 1999
22. Hiyama K, Hiyama E, Ishioka S, et al: Telomerase activity in small-cell and non-small-cell lung cancers. J Natl Cancer Inst 87:895-902, 1995
23. Salgia R, Skarin AT: Molecular abnormalities in lung cancer. J Clin Oncol 16:1207-1217, 1998
24. Battey J, Moulding C, Taub R, et al: The human c-myc oncogene: Structural consequences of translocation into the IgH locus in Burkitt lymphoma. Cell 34:779-787, 1983
25. Taub R, Kirsch I, Morton C, et al: Translocations of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells. Proc Natl Acad Sci USA 79:7837-7841, 1982
26. Dalla-Favera R, Bregni M, Erikson J, et al: Human c-myc oncogene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma. Proc Natl Acad Sci USA 79:7824-7827, 1982
27. Blackwood E, Eisenman R: Max: A helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with myc. Science 251:1211-1217, 1991
28. Lemaitre J-M, Buckle R, Mechali M: c-myc in the control of cell proliferation and embryonic development. Adv Cancer Res 70:95-144, 1996
29. Paget S: The distribution of secondary growths in cancer of the breast. Lancet 1:571-573, 1989
30. Prins J, De Vries E, Mulder N: The myc family of oncogenes and their presence and importance in small-cell lung carcinoma and other tumour types. Anticancer Res 13:1373-1385, 1993
31. Funa K, Steinholtz L, Nou E, et al: Increased expression of N-myc in human small cell lung cancer biopsies predict lack of response to chemotherapy and poor prognosis. J Clin Pathol 88:216-220, 1986
32. Noguchi M, Hirohasi S, Hara F: Heterogeneous amplification of myc family oncogenes in small cell lung carcinoma. Cancer 66:2053-2058, 1990
33. Brennan J, O'Connor T, Makuch R, et al: myc family DNA amplification in 107 tumors and tumor cell lines from patients with small cell lung cancer treated with different combination chemotherapy regimens. Cancer Res 51:1708-1712, 1991
34. Johnson BE, Ihde DC, Makuch RW, et al: myc family oncogene amplification in tumor cell lines established from small cell lung cancer patients and its relationship to clinical status and course. J Clin Invest 79:1629-1634, 1987
35. Takahashi T, Obata Y, Sekido Y, et al: Expression and amplification of myc gene family in small cell lung cancer and its relation to biological characteristics. Cancer Res 49:2683-2688, 1989
36. Sirzen F, Zhivotovsky B, Nilsson A, et al: Higher spontaneous apoptotic index in small cell compared with non-small cell lung carcinoma cell lines; lack of correlation with Bcl-2/Bax. Lung Cancer 22:1-13, 1998
37. Korsmeyer SJ: Regulators of cell death. Trends Genet 11:101-105, 1995
38. Hale AJ, Smith CA, Sutherland LC, et al: Apoptosis: Molecular regulation of cell death. Eur J Biochem 236:1-26, 1996
39. Ruvolo PP, Deng X, May WS: Phosphorylation of Bcl2 and regulation of apoptosis. Leukemia 15:515-522, 2001
40. Ohmori T, Podack ER, Nishio K, et al: Apoptosis of lung cancer cells caused by some anti-cancer agents (MMC, CPT-11, ADM) is inhibited by bcl-2. Biochem Biophys Res Commun 192:30-36, 1993
41. Kaiser U, Schilli M, Haag U, et al: Expression of bcl-2-protein in small cell lung cancer. Lung Cancer 15:31-40, 1996
42. Jiang SX, Sato Y, Kuwao S, et al: Expression of bcl-2 oncogene protein is prevalent in small cell lung carcinomas. J Pathol 177:135-138, 1995
43. Jiang SX, Kameya T, Sato Y, et al: Bcl-2 protein expression in lung cancer and close correlation with neuroendocrine differentiation. Am J Pathol 148:837-846, 1996
44. Maitra A, Amirkhan RH, Saboorian MH, et al: Survival in small cell lung carcinoma is independent of Bcl-2 expression. Hum Pathol 30:712-717, 1999
45. Brambilla E, Negoescu A, Gazzeri S, et al: Apoptosis-related factors p53, Bcl2, and Bax in neuroendocrine lung tumors. Am J Pathol 149:1941-1952, 1996
46. Banerjee D: Technology evaluation: G-3139. Curr Opin Mol Ther 1:404-408, 1999
47. Zangemeister-Wittke U, Leech SH, Olie RA, et al: A novel bispecific antisense oligonucleotide inhibiting both bcl-2 and bcl-xL expression efficiently induces apoptosis in tumor cells. Clin Cancer Res 6:2547-2555, 2000
48. Kaelin WG Jr: The p53 gene family. Oncogene 18:7701-7705, 1999
49. Tokino T, Nakamura Y: The role of p53-target genes in human cancer. Crit Rev Oncol Hematol 33:1-6, 2000
50. Mai M, Yokomizo A, Qian C, et al: Activation of p73 silent allele in lung cancer. Cancer Res 58:2347-2349, 1998
51. Nomoto S, Haruki N, Kondo M, et al: Search for mutations and examination of allelic expression imbalance of the p73 gene at 1p36.33 in human lung cancers. Cancer Res 58:1380-1383, 1998
52. Srivastava S, Zou ZQ, Pirollo K, et al: Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature 348:747-749, 1990
53. Malkin D, Li FP, Strong LC, et al: Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250:1233-1238, 1990
54. Yoshikawa H, Nagashima M, Khan MA, et al: Mutational analysis of p73 and p53 in human cancer cell lines. Oncogene 18:3415-3421, 1999
55. Sidransky D, Hollstein M: Clinical implications of the p53 gene. Annu Rev Med 47:285-301, 1996
56. Kaelin WG Jr: Recent insights into the functions of the retinoblastoma susceptibility gene product. Cancer Invest 15:243-254, 1997
57. Knudson A: Hereditary cancer: Clues to mechanisms of carcinogenesis. Br J Cancer 59:661-666, 1989
58. Flemington EK, Speck SH, Kaelin WG Jr: E2F-1-mediated transactivation is inhibited by complex formation with the retinoblastoma susceptibility gene product. Proc Natl Acad Sci USA 90:6914-6918, 1993
59. Helin K, Harlow E, Fattaey A: Inhibition of E2F-1 transactivation by direct binding of the retinoblastoma protein. Mol Cell Biol 13:6501-6508, 1993
60. Yokota J, Akiyama T, Fung Y, et al: Altered expression of the retinoblastoma (RB) gene in small cell lung cancer of the lung. Oncogene 3:471-475, 1988
61. Harbour J, Lai S, Whang-Peng J, et al: Abnormalities in structure and expression of the retinoblastoma gene in SCLC. Science 241:353-357, 1988
62. Reeve J, Payne J, Bleehen N: Production of immunoreactive insulin-like growth factor-1 (IGF-1) and IGF-1 binding proteins by human lung tumors. Br J Cancer 61:727-731, 1990
63. Minuto F, Del Monte P, Barreca A, et al: Evidence for an increased somatomedin C/insulin-like growth factor-1 content in primary human lung tumors. Cancer Res 46:985-988, 1986
64. Adams TE, Epa VC, Garrett TP, et al: Structure and function of the type 1 insulin-like growth factor receptor. Cell Mol Life Sci 57:1050-1093, 2000
65. Yu H, Spitz MR, Mistry J, et al: Plasma levels of insulin-like growth factor-1 and lung cancer risk: a case-control analysis. J Natl Cancer Inst 91:151-156, 1999
66. Matthews W, Jordan CT, Wiegand GW, et al: A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations. Cell 65:1143-1152, 1991
67. Ashman LK: The biology of stem cell factor and its receptor C-kit. Int J Biochem Cell Biol 31:1037-1051, 1999
68. Linnekin D: Early signaling pathways activated by c-Kit in hematopoietic cells. Int J Biochem Cell Biol 31:1053-1074, 1999
69. Hibi K, Takahashi T, Sekido Y, et al: Coexpression of the stem cell factor and the c-kit genes in small-cell lung cancer. Oncogene 6:2291-2296, 1991
70. Sekido Y, Obata Y, Ueda R, et al: Preferential expression of c-kit protooncogene transcripts in small cell lung cancer. Cancer Res 51:2416-2419, 1991
71. Rygaard K, Nakamura T, Spang-Thomsen M: Expression of the proto-oncogenes c-met and c-kit and their ligands, hepatocyte growth factor/scatter factor and stem cell factor, in SCLC cell lines and xenografts. Br J Cancer 67:37-46, 1993
72. Sekido Y, Takahashi T, Ueda R, et al: Recombinant human stem cell factor mediates chemotaxis of small-cell lung cancer cell lines aberrantly expressing the c-kit protooncogene. Cancer Res 53:1709-1714, 1993
73. Plummer H 3rd, Catlett J, Leftwich J, et al: c-myc expression correlates with suppression of c-kit protooncogene expression in small cell lung cancer cell lines. Cancer Res 53:4337-4342, 1993
74. Krystal GW, Hines SJ, Organ CP: Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor. Cancer Res 56:370-376, 1996
75. Yamanishi Y, Maeda H, Hiyama K, et al: Specific growth inhibition of small-cell lung cancer cells by adenovirus vector expressing antisense c-kit transcripts. Jpn J Cancer Res 87:534-542, 1996
76. Wang WL, Healy ME, Sattler M, et al: Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor ST1571. Oncogene 19:3521-3528, 2000
77. Krystal GW, Honsawek S, Litz J, et al: The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. Clin Cancer Res 6:3319-3326, 2000
78. Krystal GW, Honsawek S, Kiewlich D, et al: Indolinone tyrosine kinase inhibitors block Kit activation and growth of small cell lung cancer cells. Cancer Res 61:3660-3668, 2001
79. Kuenen BC, Rosen L, Smit EF, et al: Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. J Clin Oncol 20:1657-1667, 2002
80. Iyer A, Kmiecik TE, Park M, et al: Structure, tissue-specific expression, and transforming activity of the mouse met protooncogene. Cell Growth Differ 1:87-95, 1990
81. Rong S, Bodescot M, Blair D, et al: Tumorigenicity of the met proto-oncogene and the gene for hepatocyte growth factor. Mol Cell Biol 12:5152-5158, 1992
82. Faletto DL, Tsarfaty I, Kmiecik TE, et al: Evidence for non-covalent clusters of the c-met proto-oncogene product. Oncogene 7:1149-1157, 1992
83. Stella MC, Comoglio PM: HGF: A multifunctional growth factor controlling cell scattering. Int J Biochem Cell Biol 31:1357-1362, 1999
84. To CT, Tsao MS: The roles of hepatocyte growth factor/scatter factor and met receptor in human cancers (review). Oncol Rep 5:1013-1024, 1998
85. Schmidt L, Junket K, Weirich G, et al: Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene. Cancer Res 58:1719-1722, 1998
86. Schmidt L, Junker K, Nakaigawa N, et al: Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene 18:2343-2350, 1999
87. Maulik G, Kijima T, Ma PC, et al: Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer. Clin Cancer Res 8:620-627, 2002
88. Bardelli A, Longati P, Williams TA, et al: A peptide representing the carboxyl-terminal tail of the met receptor inhibits kinase activity and invasive growth. J Biol Chem 274:29274-29281, 1999
89. Atabey N, Gao Y, Yao ZJ, et al: Potent blockade of hepatocyte growth factor-stimulated cell motility, matrix invasion and branching morphogenesis by antagonists of Grb2 Src homology 2 domain interactions. J Biol Chem 276:14308-14314, 2001
90. Gual P, Giordano S, Williams TA, et al: Sustained recruitment of phospholipase C-gamma to Gabl is required for HGF-induced branching tubulogenesis. Oncogene 19:1509-1518, 2000
91. Sporn M, Roberts A, Wakefield L, et al: Some recent advances in the chemistry and biology of transforming growth factor-beta. J Cell Biol 105:1039-1045, 1987
92. Norgaard P, Spang-Thomsen M, Poulsen HS: Expression and autoregulation of transforming growth factor beta receptor mRNA in small-cell lung cancer cell lines. Br J Cancer 73:1037-1043, 1996
93. Heldin CH, Miyazono K, ten Dijke P: TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature 390:465-471, 1997
94. Uchida K, Nagatake M, Osada H, et al: Somatic in vivo alterations of the JV18-1 gene at 18q21 in human lung cancers. Cancer Res 56:5583-5585, 1996
95. Nagatake M, Takagi Y, Osada H, et al: Somatic in vivo alterations of the DPC4 gene at 18q21 in human lung cancers. Cancer Res 56:2718-2720, 1996
96. Riggins GJ, Kinzler KW, Vogelstein B, et al: Frequency of Smad gene mutations in human cancers. Cancer Res 57:2578-2580, 1997
97. Gerwin BI, Spillare E, Forrester K, et al: Mutant p53 can induce tumorigenic conversion of human bronchial epithelial cells and reduce their responsiveness to a negative growth factor, transforming growth factor beta 1. Proc Natl Acad Sci USA 89:2759-2763, 1992
98. Gutkind JS: Cell growth control by G protein-coupled receptors: From signal transduction to signal integration. Oncogene 17:1331-1342, 1998
99. Moody T, Pert CB, Gazdar A, et al: High levels of intracellular bombesin characterize human small cell lung carcinoma. Science 214:1246-1248, 1981
100. Spindel E, Chin W, Price J, et al: Cloning and characterization of cDNAs encoding human gastrin-releasing peptide. Proc Natl Acad Sci USA 81:5699-5703, 1984
101. Sausville E, Lebacq-Verheyden A, Spindel E, et al: Expression of the gastrin releasing peptide gene in human small cell lung cancer. J Biol Chem 261:2451-2459, 1986
102. Cuttitta F, Carney DN, Mulshine J, et al: Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer. Nature 316:823-826, 1985
103. Miyake Y, Kodama T, Yamaguchi K: Pro-gastrin-releasing peptide(31-98) is a specific tumor marker in patients with small cell lung carcinoma. Cancer Res 54:2136-2140, 1994
104. Chaudhry A, Carrasquillo JA, Avis IL, et al: Phase I and imaging trial of a monoclonal antibody directed against gastrin-releasing peptide in patients with lung cancer. Clin Cancer Res 5:3385-3393, 1999
105. Kojika S, Griffin JD: Notch receptors and hematopoiesis. Exp Hematol 29:1041-1052, 2001
106. Dang TP, Gazdar AF, Virmani AK, et al: Chromosome 19 translocation, overexpression of Notch3, and human lung cancer. J Natl Cancer Inst 92:1355-1357, 2000
107. Sriuranpong V, Borges MW, Ravi RK, et al: Notch signaling induces cell cycle arrest in small cell lung cancer cells. Cancer Res 61:3200-3205, 2001
108. Borges M, Linnoila RI, van de Velde HJ, et al: An achaete-scute homologue essential for neuroendocrine differentiation in the lung. Nature 386:852-855, 1997
109. Linnoila RI, Zhao B, DeMayo JL, et al: Constitutive achaete-scute homologue-1 promotes airway dysplasia and lung neuroendocrine tumors in transgenic mice. Cancer Res 60:4005-4009, 2000
110. Souhami R, Beverley P, Bobrow L: Proceedings of the First International Workshop on Small Cell Lung Cancer. Lancet 2:325-326, 1987
111. Souhami R, Beverley P, Bobrow L, et al: Antigens of lung cancer: Results of the Second International Workshop on Lung Cancer Antigens. J Natl Cancer Inst 83:609-612, 1991
112. Stahel R, Gilks W, Schenker T: Antigens of lung cancer: Results of the Third International Workshop on Lung Tumor and Differentiation Antigens. J Natl Cancer Inst 86:669-672, 1994
113. Moolenaar C, Muller E, Schol D: Expression of the neural cell adhesion molecule-related sialoglycoprotien in small cell lung cancer and neuroblastoma cell lines H69 and CHP-212. Cancer Res 50:1102-1106, 1990
114. Kibbelaar R, Moolenaar C, Michalides R, et al: Expression of the embryonal neural cell adhesion molecule N-CAM in lung carcinoma. Diagnostic usefulness of monoclonal antibody 735 for the distinction betweeen small cell lung cancer and non-small cell lung cancer. J Pathol 159:23-28, 1989
115. Lynch TJ Jr, Lambert JM, Coral F, et al: Immunotoxin therapy of small-cell lung cancer: A phase I study of N901-blocked ricin. J Clin Oncol 15:723-734, 1997
116. Moore SM, Rintoul RC, Walker TR, et al: The presence of a constitutively active phosphoinositide 3-kinase in small cell lung cancer cells mediates anchorage-independent proliferation via a protein kinase B and p70s6k-dependent pathway. Cancer Res 58:5239-5247, 1998
117. Carpenter CL, Cantley LC: Phosphoinositide kinases. Curr Opin Cell Biol 8:153-158, 1996
118. Rameh LE, Cantley LC: The role of phosphoinositide 3-kinase lipid products in cell function. J Biol Chem 274:8347-8350, 1999
119. Vanhaesebroeck B, Waterfield MD: Signaling by distinct classes of phosphoinositide 3-kinases. Exp Cell Res 253:239-254, 1999
120. Berrie CP: Phosphoinositide 3-kinase inhibition in cancer treatment. Expert Opin Invest Drugs 10:1085-1098, 2001
121. Stein RC: Prospects for phosphoinositide 3-kinase inhibition as a cancer treatment. Endocr Relat Cancer 8:237-248, 2001
122. Belham C, Wu S, Avruch J: Intracellular signalling: PDK1 - A kinase at the hub of things. Curr Biol 9:R93-96, 1999
123. Datta SR, Brunet A, Greenberg ME: Cellular survival: A play in three Akts. Genes Dev 13:2905-2927, 1999
124. Vanhaesebroeck B, Alessi DR: The PI3K-PDK1 connection: More than just a road to PKB. Biochem J 346 Pt 3:561-576, 2000
125. Brazil DP, Hemmings BA: Ten years of protein kinase B signalling: A hard Akt to follow. Trends Biochem Sci 26:657-664, 2001
126. Kops GJ, Burgering BM: Forkhead transcription factors: New insights into protein kinase B (c-akt) signaling. J Mol Med 77:656-665, 1999
127. Seufferlein T, Rozengurt E: Rapamycin inhibits constitutive p70s6k phosphorylation, cell proliferation, and colony formation in small cell lung cancer cells. Cancer Res 56:3895-3897, 1996
128. Hidalgo M, Rowinsky E, Erlichman C, et al: CCI-779, a rapamycin analog and multifaceted inhibitor of signal transduction: A phase I study. Proc Am Soc Clin Oncol 19:182a, 2000 (abstr 726)
129. Cantley LC, Neel BG: New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA 96:4240-4245, 1999
130. Kim SK, Su LK, Oh Y, et al: Alterations of PTEN/MMAC1, a candidate tumor suppressor gene, and its homologue, PTH2, in small cell lung cancer cell lines. Oncogene 16:89-93, 1998
131. Kohno T, Takahashi M, Manda R, et al: Inactivation of the PTEN/MMAC1/TEP1 gene in human lung cancers. Genes Chromosomes Cancer 22:152-156, 1998
132. Forgacs E, Biesterveld EJ, Sekido Y, et al: Mutation analysis of the PTEN/MMAC1 gene in lung cancer. Oncogene 17:1557-1565, 1998
133. Hong TM, Yang PC, Peck K, et al: Profiling the downstream genes of tumor suppressor PTEN in lung cancer cells by complementary DNA microarray. Am J Respir Cell Mol Biol 23:355-363, 2000
134. Basu A: The potential of protein kinase C as a target for anticancer treatment. Pharmacol Ther 59:257-280, 1993
135. Blobe GC, Obeid LM, Hannun YA: Regulation of protein kinase C and role in cancer biology. Cancer Metastasis Rev 13:411-431, 1994
136. Goekjian PG, Jirousek MR: Protein kinase C inhibitors as novel anticancer drugs. Expert Opin Invest Drugs 10:2117-2140, 2001
137. Lo SH, Chen LB: Focal adhesion as a signal transduction organelle. Cancer Metastasis Rev 13:9-24, 1994
138. Hynes RO: Integrins: Versatility, modulation, and signaling in cell adhesion. Cell 69:11-25, 1992
139. Guo N, Templeton NS, Al-Barazi H, et al: Thrombospondin-1 promotes alpha3beta1 integrin-mediated adhesion and neurite-like outgrowth and inhibits proliferation of small cell lung carcinoma cells. Cancer Res 60:457-466, 2000
140. Sethi T, Rintoul RC, Moore SM, et al: Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: A mechanism for small cell lung cancer growth and drug resistance in vivo. Nat Med 5:662-668, 1999
141. Ambros VR, Chen LB, Buchanan JM: Surface ruffles as markers for studies of cell transformation by Rous sarcoma virus. Proc Natl Acad Sci USA 72:3144-3148, 1975
142. Bernal SD, Baylin SB, Shaper JH, et al: Cytoskeleton-associated proteins of human lung cancer cells. Cancer Res 43:1798-1808, 1983
143. Salgia R, Li JL, Lo SH, et al: Molecular cloning of human paxillin, a focal adhesion protein phosphorylated by P210BCR/ABL. J Biol Chem 270:5039-5047, 1995
144. Salgia R, Li JL, Ewaniuk DS, et al: Expression of the focal adhesion protein paxillin in lung cancer and its relation to cell motility. Oncogene 18:67-77, 1999
145. Bockholt SM, Burridge K: Cell spreading on extracellular matrix proteins induces tyrosine phosphorylation of tensin. J Biol Chem 268:14565-14567, 1993
146. Salgia R, Avraham S, Pisick E, et al: The related adhesion focal tyrosine kinase forms a complex with paxillin in hematopoietic cells. J Biol Chem 271:31222-31226, 1996
147. Salgia R, Pisick E, Sattler M, et al: p130CAS forms a signaling complex with the adapter protein CRKL in hematopoietic cells transformed by the BCR/ABL oncogene. J Biol Chem 271:25198-25203, 1996
148. Schaller MD, Otey CA, Hildebrand JD, et al: Focal adhesion kinase and paxillin bind to peptides mimicking beta integrin cytoplasmic domains. J Cell Biol 130:1181-1187, 1995
149. Adler V, Yin Z, Tew KD, et al: Role of redox potential and reactive oxygen species in stress signaling. Oncogene 18:6104-6111, 1999
150. Kamata H, Hirata H: Redox regulation of cellular signalling. Cell Signal 11:1-14, 1999
151. Rahman I, MacNee W: Role of oxidants/antioxidants in smoking-induced lung diseases. Free Radic Biol Med 21:669-681, 1996
152. Guan KL, Dixon JE: Evidence for protein-tyrosine-phosphatase catalysis proceeding via a cysteine-phosphate intermediate. J Biol Chem 266:17026-17030, 1991
153. Barrett WC, DeGnore JP, Keng YF, et al: Roles of superoxide radical anion in signal transduction mediated by reversible regulation of protein-tyrosine phosphatase 1B. J Biol Chem 274:34543-34546, 1999
154. ras interaction. J Biol Chem 272:4323-4326, 1997
155. Suh Y-A, Arnold RS, Lassegue B, et al: Cell transformation by the superoxide-generating oxidase Moxl. Nature 401:79-82, 1999
156. Huang P, Feng L, Oldham EA, et al: Superoxide dismutase as a target for the selective killing of cancer cells. Nature 407:390-395, 2000